Typical Dosing and Administration Protocols

Based on available clinical trial evidence, retatrutide dosing protocols vary depending on the indication and study population. The evidence for specific dosing regimens comes primarily from ongoing and completed Phase 1 and Phase 3 clinical trials.

Current Clinical Trial Dosing:

Clinical trials are investigating various dose ranges and escalation schedules
Studies include both diabetes (TRANSCEND-T2D-1) and obesity populations
Specific dosing details from completed trials have not been published in the available literature

Administration Route:

Retatrutide appears to be administered as a subcutaneous injection based on clinical trial designs
Frequency and injection site protocols follow patterns typical of other incretin-based therapies

Dose Escalation:

Like other GLP-1 receptor agonists and multi-receptor agonists, retatrutide likely follows a gradual dose escalation protocol to minimize gastrointestinal side effects
Specific escalation schedules have not been detailed in the available published literature

Special Populations:

Phase 1 studies have examined retatrutide in participants with impaired renal function (NCT05611957)
Drug interaction studies with metoprolol have been completed (NCT06808802)

Evidence Limitations:
The available literature provides limited specific details about standardized dosing protocols, as most clinical trials are recently completed or still ongoing. Detailed dosing information from pivotal Phase 3 trials has not yet been published in peer-reviewed journals.

Important Disclaimer: This information is for educational purposes only and represents investigational protocols from clinical trials. This is not personalized medical advice. Retatrutide is not yet approved for clinical use. Any treatment decisions should be made in consultation with qualified healthcare providers who can assess individual medical circumstances and provide appropriate guidance.

Retatrutide

Member access required